The question matters because prurigo nodularis is far from rare and far from benign. Clinicians have historically viewed it as a disfiguring, quality-of-life-destroying disorder driven by a self-perpetuating itch-scratch cycle, but over the past decade a growing body of work has suggested that the disease may travel with systemic baggage. Earlier clinical observations, including a widely cited 2019 analysis in the Journal of the American Academy of Dermatology by Larson and colleagues, reported an association between prurigo nodularis and malignancy in middle-aged adults, prompting dermatologists to wonder whether the condition might serve as a cutaneous flag for internal disease. Subsequent systematic reviews, including a 2025 meta-analysis by Chang and Chiu in the Journal of the European Academy of Dermatology and Venereology, have examined the risk of malignancy in prurigo nodularis patients, keeping the controversy alive in the literature.

What has made the field difficult is confounding. Patients with prurigo nodularis tend to be older, more likely to have atopic dermatitis and other inflammatory conditions, more likely to take immunomodulating drugs, and more likely to see physicians frequently, which increases the chance that any cancer will simply be noticed. A naive comparison of cancer rates between prurigo nodularis patients and the general population could therefore exaggerate or even invent an association. This is precisely the methodological trap that propensity score matching is designed to defuse. By estimating each participant’s probability of having prurigo nodularis based on measured characteristics, and then matching each case to controls with similar probabilities, the technique creates two groups that are statistically balanced on the measured confounders, allowing the disease itself to be isolated as the variable of interest.

The data infrastructure behind the new analysis is as important as the statistics. The All of Us Research Program, launched by the National Institutes of Health and described in the New England Journal of Medicine in 2019 by Denny and colleagues, aims to enroll at least one million Americans and deliberately prioritizes populations that have been underrepresented in biomedical research. Its curated database links electronic health records, survey responses, and physical measurements, giving researchers a way to study real-world patient populations at a scale that single-center clinics cannot match. For a condition like prurigo nodularis, which is often underdiagnosed and inconsistently coded, access to a large, diverse cohort is a meaningful advantage over the smaller case series that dominated the earlier literature.

Using this resource, the Baylor team constructed a cohort of individuals with prurigo nodularis and a matched comparison group without the disease, then tracked the occurrence of skin cancer across the two groups. The outcome of interest, skin cancer, encompasses both keratinocyte malignancies such as basal cell and squamous cell carcinoma and the more dangerous melanoma, and the researchers’ framing of the study reflects a broader question in dermatology: whether chronic Th2-skewed inflammatory dermatoses, the immune signature that prurigo nodularis shares with atopic dermatitis, alter cancer surveillance and tumor biology in the skin. A 2025 review in the International Journal of Molecular Sciences underscored the central role of type 2 immune responses in inflammatory dermatoses, from pathogenesis to the new wave of targeted therapies, providing a biological rationale for why chronic itch disorders might intersect with oncology.

The study’s findings, presented as a research letter rather than a full-length paper, should be read with an appreciation of both their strengths and their limits. Research letters are compact formats that report focused analyses, and the authors are explicit that their work is observational. Propensity score matching balances the confounders that are measured, but it cannot eliminate residual confounding by factors that were never recorded, such as lifetime ultraviolet exposure, sun-protection behavior, or the precise duration and severity of itch. Skin cancer risk is overwhelmingly driven by ultraviolet radiation, and any study that cannot fully adjust for sun exposure must interpret its own associations with appropriate humility. The authors declare no conflicts of interest relevant to the work, and the research received no specific grant funding from public, commercial, or not-for-profit agencies.

Nevertheless, the direction of the evidence is becoming harder to ignore. The new All of Us analysis lands in a literature that has repeatedly circled the same question from different angles: clinic-based series suggesting excess malignancy, meta-analyses attempting to pool the signal, and now a large, matched, nationally representative cohort designed specifically to neutralize demographic and comorbidity differences. Convergent findings across independent datasets and methods are how epidemiology builds confidence, and the Baylor study adds a methodologically careful data point to that convergence. For dermatologists, the practical implication is that prurigo nodularis may deserve a place in the same conversation as other inflammatory skin diseases, such as severe psoriasis and atopic dermatitis, for which guidelines increasingly recommend attention to comorbidity screening.

The biological plausibility of a link deserves scrutiny as well. Chronic inflammation is a recognized contributor to carcinogenesis across many tissues, and the skin is no exception: inflamed microenvironments supply proliferative signals, oxidative stress, and immune modulation that can favor tumor initiation and progression. Prurigo nodularis lesions are characterized by thickened, hyperproliferative epidermis, nerve fiber proliferation, and a persistent type 2 immune infiltrate, and many patients are treated with systemic agents that modulate immunity. Whether the association with skin cancer, if confirmed, reflects shared inflammatory pathways, behavioral factors such as scratching and skin barrier disruption, surveillance bias, or the effects of immunosuppressive therapy remains an open question that the research letter cannot resolve on its own.

What the study does resolve is the feasibility of asking these questions at scale. By demonstrating that the All of Us Research Program can support propensity score–matched analyses of an underrecognized skin disease, the Baylor team has opened a template for follow-up work: larger cohorts, longer follow-up, subtype-specific cancer outcomes, and stratification by race, ethnicity, and skin type, where the burden of prurigo nodularis is known to be disproportionately high among Black and other patients of color yet where melanoma detection patterns differ. The authors, based at Baylor College of Medicine and McGovern Medical School at UTHealth Houston, note that the manuscript went through revision and was accepted in September 2026, reflecting an active and current debate in the dermatology community.

For patients living with the relentless itch of prurigo nodularis, the message from this research is not alarm but attention. The disease is already associated with anxiety, depression, sleep loss, and profound impairment of daily life, and the possibility of an added cancer risk gives patients and clinicians one more reason to pursue early diagnosis and aggressive, modern treatment, including the biologic therapies now reshaping the field. At the same time, the study is a reminder of how much remains unknown: an association established in a matched cohort is a signal to investigate, not a prescription for panic. As the All of Us database continues to grow and as targeted anti-itch therapies generate new natural experiments in immune modulation, the coming years should clarify whether prurigo nodularis truly belongs on the list of inflammatory skin diseases with oncologic consequences, and if so, what mechanisms connect a scratch to a tumor.

Subject of Research: Association between prurigo nodularis and skin cancer risk in a propensity score–matched cohort from the All of Us Research Program

Article Title: Association between prurigo nodularis and skin cancer: a propensity score–matched cohort study using the all of us research program

Article References: K Joe, M., Husseinali, M., & A Wasko, C. (2026). Association between prurigo nodularis and skin cancer: a propensity score–matched cohort study using the all of us research program. Archives of Dermatological Research, 318(1), Article 509. https://doi.org/10.1007/s00403-026-04989-7

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04989-7

Keywords: prurigo nodularis, skin cancer, All of Us Research Program, propensity score matching, dermatology, chronic itch, melanoma, inflammatory skin disease, epidemiology, cohort study, Th2 immune response, comorbidity